GAOMA develops new therapeutic molecules, with a particular focus on epilepsy and cognitive disorders. GAO-3-02 is a novel patented active ingredient, with an innovative MoA for the treatment of epilepsy. In various preclinical PoC studies, it demonstrated its ability to limit seizures but also to protect/restore cognitive functions, both on the long term. The company will also rapidly explore the interest of GAO-3-02 in other indications.